On February 11, Abbott Laboratories, a pharmaceuticals health care company, announced that the U.S. Food and Drug Administration had approved a new version of their anti-HIV medication, Norvir (ritonavir).

Norvir is a drug of the antiretroviral medication class known as protease inhibitors (PI). It is generally used as a “booster” drug to enhance the effects of other antiretroviral medications in order to prevent drug resistance in HIV-positive individuals.

The newly FDA approved formulation of Norvir is a heat-stable version, which means that the tablets do not require refrigeration to be…